



Dkt. 1795/57743-A-PCT-US JPWZUXH

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

SEP 23 2002

RECEIVED

#7
1614
10/22/03
89/

Applicants : Mohammad Marzabadi et al.
U.S. Serial No.: 10/009,849 ✓
Filed : October 22, 2001
For : Selective NPY (Y5) Antagonists ✓

1185 Avenue of the Americas
New York, New York 10036
September 17, 2002

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

This Second Supplemental Information Disclosure Statement is submitted to supplement the Information Disclosure Statements filed January 22, 2002, and August 16, 2002 in connection with the subject application.

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the following disclosures which are listed on the attached Form PTO-1449 (**Exhibit A**):

1. U.S. Patent No. 3,128,272 (Wear, R. L., et al.), issued April 7, 1964;
2. German Patent No. DE 19,824,175 (Novartis AG), published December 2, 1999 (**Exhibit 1**);
3. PCT International Application Publication No. WO 01/23389 (Hodgetts, K., et al.), published April 5, 2001;
4. PCT International Application Publication No. WO 00/68197 (Dax, S., et al.), published November 16, 2000 (**Exhibit 2**);
5. PCT International Application Publication No. WO 99/62892 (Novartis AG), published December 9, 1999 (**Exhibit 3**);
6. PCT International Application Publication No. WO99/32466 (Buehlmayer, P.), published July 1, 1999;

Applicants: Mohammad Marzabadi et al.
U.S. Serial No.: 10/009,849
Filed: October 22, 2001
Page 2

7. PCT International Application Publication No. WO 97/20823 (Criscione, L., et al.), published June 12, 1997;
8. PCT International Application Publication No. WO 97/19682 (Ping, D., et al.), published June 5, 1997 (**Exhibit 4**);
9. McNally, J., et al., "N-(Sulfamido)alkyl[tetrahydro-1-H-benzo[e]indol-2-yl]amines: Potent Antagonists of Human Neuropeptide Y Y5 Receptor," *Bioorganic & Medicinal Chemistry Letters* **2000**, Vol. 10, p.p. 213-216.

Above-listed references 1, 3, and 9 were submitted to the U.S. Patent and Trademark Office on August 16, 2002 in a Supplemental Information Disclosure Statement in connection with the subject application. Above-listed references 6 and 7 were previously cited in connection with the prosecution of U.S. Serial No. 09/296,332, filed April 22, 1999, which issued as U.S. Patent No. 6,340,683 B1 on January 22, 2002; the subject application claims priority under 35 U.S.C. §120 of the filing date of that application. According to 37 C.F.R. §1.98(d), copies of patents or publications that were previously cited by, or submitted to, the Patent Office in connection with such prior applications need not accompany the Information Disclosure Statement. Accordingly, copies of references 1, 3, 6, 7, and 9 are not attached to this Second Supplemental Information Disclosure Statement.

Above-listed references 2, 4, and 8 (**Exhibits 1, 2, and 4**, respectively), were cited in a Supplementary European Search Report issued August 14, 2002 in connection with European Patent Application 00923566.4; a copy of the Search Report is attached hereto as **Exhibit 5**. Additionally, reference 5 is an English language equivalent of German reference 2, and a copy is thus attached hereto as **Exhibit 3**.


If a telephone interview would be of assistance in advancing

Applicants: Mohammad Marzabadi et al.
U.S. Serial No.: 10/009,849
Filed: October 22, 2001
Page 3

prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone the number provided below.


Applicants are filing this Second Supplemental Information Disclosure Statement under 37 C.F.R. §1.97(b)(3) before the mailing of a first Office Action on the merits. Accordingly, no fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any fee is deemed necessary, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:
Assistant Commissioner for Patents,
Washington, D.C. 20231.



John P. White
Reg. No. 28,678

9/17/02
Date

SEP 20 2002

Sheet 1 of 1

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
1795/57743-A-PCT-
US/JPW/JXHSerial No.
10/009,849**INFORMATION DISCLOSURE CITATION**
(Use several sheets if necessary)Applicant
Mohammad Marzabadi, et al.Filing Date
October 22, 2001

Group Art Unit

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
US	3 1 2 8 2 7 2	04/07/64	Wear et al.			

RECEIVED
SEP 23 2002
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
DE	19 8 2 4 1 7 5	12/02/99	Germany				
WO	0 1 2 3 3 8 9	04/05/01	PCT				
WO	0 0 6 8 1 9 7	11/16/00	PCT				
WO	9 9 6 2 8 9 2	12/09/99	PCT				
WO	9 9 3 2 4 6 6	07/01/99	PCT				
WO	9 7 2 0 8 2 3	06/12/97	PCT				
WO	9 7 1 9 6 8 2	06/05/97	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	McNally, J., et al., "N-(Sulfonamido)alkyl[tetrahydro-1 H-benzo[e]indol-2-yl]amines: Potent Antagonists of Human Neuropeptide Y Y5 Receptor," <i>Bioorganic & Medicinal Chemistry Letters</i> 2000, Vol. 10, p.p. 213-216

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicants: Mohammad R. Marzabadi et al.
U.S. Serial No. 10/009,849
Filed: October 22, 2001
Exhibit A